Journey Medical Corporation is a drug manufacturers - specialty & generic business based in the US. Journey Medical Corporation shares (DERM) are listed on the NASDAQ and all prices are listed in US Dollars. Journey Medical Corporation employs 41 staff and has a trailing 12-month revenue of around $77.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.68 |
|---|---|
| 52-week range | $1.92 - $8.11 |
| 50-day moving average | $5.17 |
| 200-day moving average | $4.67 |
| Wall St. target price | $9.17 |
| PE ratio | 38.3077 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.13 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.68 from 2024-09-06
| 1 week (2024-08-30) | -6.02% |
|---|---|
| 1 month (2024-08-09) | -6.02% |
| 3 months (2024-06-07) | -0.43% |
| 6 months (2024-03-08) | 35.65% |
| 1 year (2023-09-08) | 58.64% |
|---|---|
| 2 years (2022-09-09) | 46.71% |
| 3 years (2021-09-05) | N/A |
| 5 years (2019-09-05) | N/A |
Valuing Journey Medical Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Journey Medical Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Journey Medical Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, Journey Medical Corporation shares trade at around 38x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Journey Medical Corporation's P/E ratio is best considered in relation to those of others within the drug manufacturers - specialty & generic industry or those of similar companies.
Journey Medical Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.4 million.
The EBITDA is a measure of a Journey Medical Corporation's overall financial performance and is widely used to measure a its profitability.
To put Journey Medical Corporation's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $77.7 million |
|---|---|
| Gross profit TTM | $42.9 million |
| Return on assets TTM | 1.97% |
| Return on equity TTM | 14.92% |
| Profit margin | 1.09% |
| Book value | $0.56 |
| Market Capitalization | $103.2 million |
TTM: trailing 12 months
We're not expecting Journey Medical Corporation to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Journey Medical Corporation's shares have ranged in value from as little as $1.92 up to $8.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Journey Medical Corporation's is 0.935. This would suggest that Journey Medical Corporation's shares are less volatile than average (for this exchange).
To put Journey Medical Corporation's beta into context you can compare it against those of similar companies.
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.